Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PDGFRA rearrangements status confers therapeutic sensitivity to Imatinib in patients with Myeloproliferative Neoplasm.
This statement is based on a regulatory approval from the Health Canada:
GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.